ClinicalTrials.gg
RecruitingNCT06433284MACROHOLEUpdated Sep 9, 2026

Comparative Study of Decellularized Human Amniotic Membrane Hydrogel and Inverted Internal Limiting Membrane Flap in Idiopathic Large Macular Holes

An interventional study of 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade and 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling with amniotic membrane hydrogel filling and SF6 tamponade in Macular Holes, sponsored by Walailak University. Recruiting at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Walailak University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The human amniotic membrane (hAM) patch, introduced by Rizzo et al. in 2018, showed a 100% anatomical success rate for large or failed macular holes over a 6-month follow-up. Despite its regenerative properties like promoting angiogenesis and having low immunogenicity, its clinical use is limited by challenges such as trimming to fit small holes and complications during insertion. To overcome these issues, decellularized amniotic membrane (dAM) has been processed into a hydrogel form, enhancing its applicability and allowing it to be used as an injectable hydrogel for minimally invasive therapies. While dAM hydrogels have been used in various medical fields, their application in intraocular surgery is new. This study proposes using dAM hydrogel for large macular hole closure, comparing its effectiveness to the inverted ILM flap technique in a randomized controlled trial.

Read the detailed description

A macular hole (MH) is a neuroepithelial defect in the macular area of the retina. The estimation of macular hole incidence about 33 of every 10,000 person in individuals older than 55 years old1. The female-to-male ratio is 2 to 3:1. Idiopathic macular hole (IMH) is MHs occurring independently of primary ocular diseases such as trauma and vitreoretinopathy2 and represents the predominant subtype of MH, constituting approximately 83%1. There is a 5% to 15% risk of developing macular hole in the other eye if a macular hole develops in one eye.1 In 1988, Gass proposed a classification system for idiopathic macular holes, as well as a new hypothesis for its pathogenesis, which emphasizes the role of the vitreo-macular tangential traction in the formation of macular holes3. Macular hole closure can occurred spontaneously in approximately 5-10% cases in early stages. Pars plana vitrectomy with internal limiting membrane (ILM) peeling and gas tamponade has been the standard of care of small size macular hole treatment with success rate more than 90%4. However, in large macular hole more than 400 um, the success rate is lower. Previous study showed closure rate of large macular hole > 400 μm is 56% with poor visual outcome.4,5 Several new techniques have been described to improve anatomical and functional outcomes in cases of large macular holes by inserting alternative tissues into the macular hole, such as the ILM flap, human amniotic membrane patch6, or retinal tissue implantation, to promote anatomical closure and improve visual acuity. The utilization of ILM flap coverage has emerged as an effective surgical approach for treating large, full-thickness idiopathic MH and myopic MH. This technique was initially introduced in 1999, showing promising results in enhancing macular hole closure rates through ILM peeling. Several subsequent studies 7-9 have further substantiated the efficacy of ILM flap coverage, making it the standard surgical treatment for large macular hole cases. However, this technique is often hindered by limitations related to the technical complexity of surgery and the risk of retinal trauma.

The human amniotic membrane (hAM) patch, proposed by Rizzo et al. in 20186, serves as another alternative technique for large or failed macular hole cases. The anatomical success rate was 100% during the 6 months follow-up. The exceptional biological properties of hAM, including its promote angiogenesis10, low immunogenicity11, and anti-inflammatory11,12, anti-fibrotic13, and antibacterial characteristics14, make it highly suitable for regenerative medicine and intraocular implantation. However, the clinical application of thin hAM sheets is limited by several challenges, such as the difficulty of trimming it to fit very small hole sizes (\< 0.2 cm), tissue loss after insertion into the PPV port, and complications during the insertion of the hAM patch into the hole. To address these limitations, processing decellularized amniotic membrane (dAM) tissue into a hydrogel form has enhanced its processability and applicability15. This transformation allows it to be used as an injectable hydrogel for minimally invasive therapies and facilitates its manipulation into the macular hole.

dAM hydrogels have been applied in various fields, including skin repair, cardiac treatment, cartilage regeneration, endometrial regeneration, vascular grafts, dental pulp regeneration, and as cell culture/carrier platforms. However, their use in intraocular surgery has not yet been established. Additionally, the benefits of dAM hydrogel over hAM tissue include lower immunogenicity due to the decellularization process since the resident cells may cause intense host immunologic reactions after transplantation and transplant rejection and the homogeneous distribution of biochemical substances within the hydrogel structure.15 In this study, we will be the first to propose a new technique and invention for closing large macular holes using human amniotic membrane hydrogel filling in the hole after standard ILM peeling. We conducted a randomized controlled trial to compare the anatomical and visual outcomes of the inverted ILM flap technique (IFT) with the dAM hydrogel technique in idiopathic large macular holes with a minimum diameter (MD) greater than 400 μm.

In vitro biological characterization of dAM hydrogel, including RPE-1 retinal pigment epithelial cell viability (CCK-8 assay at 24 and 48 hours) and scaffold-guided cell migration (transwell invasion assay), is performed at the Department of Physiology, Faculty of Medical Science, Naresuan University, as part of batch quality control prior to clinical use. Batch release requires RPE-1 cell surface viability at 48 hours to be not significantly different from Matrigel reference scaffold (one-way ANOVA, p = ns), consistent with active cell migration into the three-dimensional scaffold rather than cytotoxicity. This study is conducted under IRB approval No. WUEC-24-331-01 (Amendment No. 1, effective 1 May 2025).

02

Conditions studied

  • Macular Holes

Browse trials for

Keywords

  • macular holes
  • decellularized amniotic membrane
  • human amniotic membrane hydrogel
  • vitrectomy
  • inverted ILM flap
  • randomized controlled trial
03

In context

Retinal Perforations

139 studies on the registry are indexed under Retinal Perforations; 22 are open to participants now.

This study's planned enrollment of 26 is below the median of 50 across 94 interventional studies indexed under Retinal Perforations.

Browse Retinal Perforations studies →

Lead sponsor

Walailak University is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age ≥18 years Idiopathic full-thickness macular hole with minimum diameter >400 µm confirmed on SD-OCT Willing and able to provide written and comply with 6-month follow-up schedule

Exclusion criteria

Exclusion Criteria:

Full-thickness macular hole with minimum diameter >1,500 µm Traumatic macular holes Myopic macular holes (axial length >26.5 mm or refractive error less than -8.0 diopters) Co-existing ocular pathologies independently affecting visual acuity (glaucoma with visual field loss, advanced age-related macular degeneration, diabetic macular edema, or epiretinal membrane requiring surgery) Active intraocular inflammation or infection Previous vitreoretinal surgery Medical unfitness for local anesthesia surgery as determined by the anesthesiologist Inability to maintain prone positioning postoperatively

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
26 participants (estimated)

Study arms

  • Active comparator
    Inverted flap

    Patients who will undergo 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade.

    Procedure: 25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade

  • Experimental
    Amniotic membrane hydrogel

    Patients who will undergo 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling, amniotic membrane hydrogel filling and SF6 tamponade.

    Procedure: 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling with amniotic membrane hydrogel filling and SF6 tamponade

Interventions

  • Procedure25-gauge pars plana vitrectomy with inverted flap technique and SF6 tamponade

    Standard 3 port 25-gauge pars plana vitrectomy with inverted flap technique after brilliant blue dye staining and SF6 tamponade. "Flower petal" type of inverted flap will be performed - multiple small ILM flaps will be created around the macular hole and placed over the macular hole

  • Procedure25-gauge pars plana vitrectomy with complete internal limiting membrane peeling with amniotic membrane hydrogel filling and SF6 tamponade

    Standard 3 port 25-gauge pars plana vitrectomy with complete internal limiting membrane peeling around the macular hole after brilliant blue dye staining then filling the hole with amniotic membrane hydrogel and sulfur hexafluoride (SF6) tamponade

06

What researchers measure

Primary outcomes

  1. Closure rate

    Type 1 anatomical closure rate at 6 months postoperatively, defined per the Gigante et al. classification as complete flattening of the macular hole with neurosensory retina fully covering the retinal pigment epithelium across the fovea on SD-OCT, assessed by a masked investigator on anonymized images.

    Time frame: 6 months

Secondary outcomes

  1. Best corrected visual acuity (BCVA)

    Change in best-corrected visual acuity (BCVA) from baseline to 6 months postoperatively, measured in logMAR by a masked assessor, comparing dAM hydrogel instillation versus inverted ILM flap technique.

    Time frame: 6 months

  2. EZ and ELM integrity

    Ellipsoid zone (EZ) integrity grade (Continuous/Discontinuous/Absent) and external limiting membrane (ELM) continuity (Continuous/Discontinuous) at 6 months postoperatively on SD-OCT, graded by a masked investigator on anonymized images.

    Time frame: 6 months

  3. Intraocular pressure (IOP)

    Change in intraocular pressure (IOP) from baseline to 6 months postoperatively, measured by Goldmann applanation tonometry.

    Time frame: 6 months

  4. Intraoperative and postoperative complications

    Incidence of intraoperative and postoperative complications including intraocular inflammation (graded by SUN criteria), endophthalmitis, retinal detachment, elevated IOP requiring treatment, and cataract progression requiring surgery.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Jakkrit Juhong
    Nakhon Si Thammarat, Thasala 80160, Thailand
    Recruiting
    • Jakkrit Juhong, MD · Contactjakkrit.ju@wu.ac.th · +66816773406
    • Jakkrit Juhong, MD · Principal investigator
    • Auemphon Mormuang, PhD · Sub investigator
    • Hathaichanok Impheng, PhD · Sub investigator
08

References and documents

Publications

  • Michalewska Z, Michalewski J, Adelman RA, Nawrocki J. Inverted internal limiting membrane flap technique for large macular holes. Ophthalmology. 2010 Oct;117(10):2018-25. doi: 10.1016/j.ophtha.2010.02.011. Epub 2010 Jun 11. PubMed 20541263 ↗
  • Juhong J, Impheng H, Sukhang M, Mordmuang A. First-in-human application of decellularized human amniotic membrane hydrogel as an injectable intraocular scaffold for large idiopathic full-thickness macular hole closure: four-month clinical outcomes. Int J Retina Vitreous. 2026 Jun 24. doi: 10.1186/s40942-026-00893-4. Online ahead of print. PubMed 42343490 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Aug 2026, 22 months after the start.

Of 45 non-industry interventional studies with no phase under Retinal Perforations, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's planned 22 months is below that.

Counting every sponsor, half of 45 studies reached it within 28 months; a quarter within 12 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2024
First posted
May 29, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Aug 30, 2026
CompletionEst.
Jan 30, 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06433284
Lead sponsor
Walailak University
Collaborators
Naresuan University
Responsible party
Jakkrit Juhong (Head of Vitreoretinal unit, Ophthalmology department, Walailak University, Walailak University) — Principal investigator
First posted
May 29, 2024
Start date
Oct 1, 2024
Primary completion
Aug 30, 2026 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

Jakkrit Juhong, MD.
Contact
jakkrit.ju@wu.ac.th
+66816773406
Jakkrit Juhong, MD.
principal investigator · School of Medicine, Walailak university

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion